Loading…
Royalty Pharma plc is projected to rise to $70.96 by 2027, a +31% move from its current price of $53.97. RPRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $53.42 | $53.96 | $54.51 | -0.02% |
| May 30 | $53.18 | $53.95 | $54.72 | -0.04% |
| May 31 | $53.00 | $53.94 | $54.89 | -0.06% |
| Jun 1 | $52.85 | $53.92 | $55.02 | -0.09% |
| Jun 2 | $52.71 | $53.91 | $55.14 | -0.11% |
| Jun 3 | $52.58 | $53.90 | $55.25 | -0.13% |
| Jun 4 | $52.47 | $53.89 | $55.35 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $52.47 | $53.89 | $55.35 | -0.15% |
| Week 2 | $51.81 | $53.81 | $55.88 | -0.30% |
| Week 3 | $51.30 | $53.73 | $56.28 | -0.45% |
| Week 4 | $50.86 | $53.65 | $56.60 | -0.59% |
| Week 5 | $50.46 | $53.57 | $56.87 | -0.74% |
| Week 6 | $50.10 | $53.49 | $57.11 | -0.89% |
| Week 7 | $49.76 | $53.41 | $57.32 | -1.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc (RPRX) is the asset with a current price of $54.50 and a market cap of $31.38B. It is ranked 432 in market position. The price outlook combines a bullish technical posture with a 30-day trading window that highlights key support and resistance levels around the current level.
The 30-day technical backdrop shows a bullish tilt, with the RSI at 70 and moving averages nearby. The stock’s near-term range and notable levels frame further upside potential, while a defined support at $48.43 and resistance at $54.50 anchors trade decisions.
The longer horizon forecast projects steady, meaningful price growth from 2026 through 2050, with the 2026 average price at $54.50 and a 2050 average price of $1,011.48. Implied ROIs rise from 0% in 2026 to 1,755.9% by 2050, signaling a long-run bullish trajectory.
A major floor 27.6% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.0% away) — a breakout level to watch.
A major ceiling 8.1% above — clearing it would confirm fresh momentum.
Key RPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $53.79 | Buy | $53.71 | Buy |
| MA 10 | $53.29 | Buy | $53.15 | Buy |
| MA 20 | $51.88 | Buy | $52.13 | Buy |
| MA 50 | $49.46 | Buy | $49.84 | Buy |
| MA 100 | $46.36 | Buy | $47.00 | Buy |
| MA 200 | $41.86 | Buy | $43.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.09 | Neutral |
| Stoch RSI (14) | 47.07 | Neutral |
| CCI (20) | 98.76 | Neutral |
| Williams %R (14) | -12.33 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 6.26 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 87.67 | Sell |
| TRIX (15) | 0.35 | Buy |
| Awesome (5,34) | 3.05 | Buy |
| Ultimate (7,14,28) | 66.50 | Neutral |
| Momentum (10) | 2.27 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 54.40 | Sell |
| ADX (14) | 33.43 | Buy |
| ATR (14) | 0.52 | Info |
The 30-day picture for RPRX is bullish. RSI14 sits at 70, signaling strong momentum within the current cycle. Theasset trades above the SMA50 of $49.13 and well above the SMA200 of $41.70, suggesting constructive price dynamics in the near term.
Key levels to watch include a support at $48.43 and a resistance at $54.50. The 30-day range runs from a low of $50.90 to a high of $58.36, highlighting a healthy price dispersion and upside potential within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $38.86 | $53.97 | $73.42 | 0% | Neutral | |
| $57.97 | $70.96 | $90.92 | +31% | Bullish | |
| $70.81 | $88.26 | $116.04 | +64% | Bullish | |
| $89.91 | $113.76 | $152.68 | +111% | Bullish | |
| $108.07 | $138.56 | $189.26 | +157% | Bullish | |
| $116.85 | $151.63 | $210.33 | +181% | Bullish | |
| $129.08 | $169.38 | $238.26 | +214% | Bullish | |
| $143.91 | $190.82 | $271.85 | +254% | Bullish | |
| $156.90 | $210.09 | $302.85 | +289% | Bullish | |
| $192.14 | $259.70 | $378.51 | +381% | Bullish | |
| $277.83 | $391.60 | $597.93 | +626% | Bullish | |
| $661.55 | $999.88 | $1,636.08 | +17.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $38.86 | $53.97 | $63.14 | +0.00% |
| June 2026 | $45.57 | $53.16 | $63.22 | -1.50% |
| July 2026 | $45.11 | $52.93 | $63.54 | -0.43% |
| August 2026 | $46.38 | $54.66 | $66.09 | +3.26% |
| September 2026 | $47.01 | $55.61 | $67.64 | +1.74% |
| October 2026 | $46.83 | $55.59 | $67.98 | -0.04% |
| November 2026 | $48.04 | $57.19 | $70.27 | +2.88% |
| December 2026 | $49.82 | $59.49 | $73.42 | +4.02% |
Click any year to see its month-by-month RPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RPRX could reach as high as $73.42, with a base case around $53.97 and support toward $38.86 — roughly 0% from $53.97. A consolidation phase looks the most probable path here.
Expect RPRX to range from $57.97 to $90.92 through 2027. The $70.96 average target implies a +31% move from current prices. That is up +31% on the projected 2026 average. Momentum favours further upside here.
The RPRX price prediction for 2028 points to an average of $88.26 (low $70.81, high $116.04) — a potential gain of +64% on today's $53.97. Buyers look set to stay in control over this stretch.
In 2029, RPRX is projected to trade between $89.91 and $152.68, averaging $113.76 — a potential gain of +111% from today's $53.97. That is up +29% on the projected 2028 average. Momentum favours further upside here.
Royalty Pharma plc's 2030 outlook centres on $138.56, within a $108.07 to $189.26 range. That is up +22% on the projected 2029 average. That marks a +157% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RPRX could reach as high as $210.33, with a base case around $151.63 and support toward $116.85 — roughly +181% from $53.97. Momentum favours further upside here.
Expect RPRX to range from $129.08 to $238.26 through 2032. The $169.38 average target implies a +214% move from current prices. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RPRX price prediction for 2033 points to an average of $190.82 (low $143.91, high $271.85) — a potential gain of +254% on today's $53.97. Momentum favours further upside here.
In 2034, RPRX is projected to trade between $156.90 and $302.85, averaging $210.09 — a potential gain of +289% from today's $53.97. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Royalty Pharma plc's 2035 outlook centres on $259.70, within a $192.14 to $378.51 range. That is up +24% on the projected 2034 average. That marks a +381% change versus current levels. Momentum favours further upside here.
By 2040, RPRX could reach as high as $597.93, with a base case around $391.60 and support toward $277.83 — roughly +626% from $53.97. Buyers look set to stay in control over this stretch.
Expect RPRX to range from $661.55 to $1,636.08 through 2050. The $999.88 average target implies a +17.5x move from current prices. That is up +155% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RPRX today (≈ 18.528812 RPRX) could be worth
$18,526.65
+$17,526.65 (+1753%) by 2050 · US Dollar
Based on the average projected RPRX price of $999.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RPRXwould be worth at today's price.
$1,000 invested in RPRX on May 27, 2025 (≈ 30.590396 RPRX) would be worth
$1,650.96
+$650.96 (+65.1%) today · 1.65× · US Dollar
Based on a RPRX entry price of $32.69 vs. today's $53.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $53.06 | $1,017.15 | +1.7% |
| 1 month ago | $49.65 | $1,087.01 | +8.7% |
| 3 months ago | $45.36 | $1,189.81 | +19.0% |
| 6 months ago | $40.02 | $1,348.58 | +34.9% |
| 1 year ago | $32.69 | $1,650.96 | +65.1% |
| All time (5.0y) ago | $40.28 | $1,339.87 | +34.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RPRX forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $48.76B
The multi-year forecast lays out a clear bullish trajectory across several years. In 2026, the average price is $54.50 with a min of $38.86 and a max of $74.44, and the ROI is 0 with a neutral sentiment. From 2027 onward, the outlook strengthens: 2027 average $71.44, 2028 $89.94, and 2029 $115.43, with ROIs of 31.1, 65, and 111.8 respectively, all bullish.
By 2030 the average price is projected at $139.80 with a min of $109.01, a max of $190.99 and ROI of 156.5, keeping a bullish sentiment. The path continues higher through 2031–2050, with 2031 avg $153.99 and ROI 182.6, 2032 avg $171.25 and ROI 214.2, 2033 avg $192.85 and ROI 253.8, 2034 avg $213.84 and ROI 292.4, 2035 avg $262.67 and ROI 382, 2040 avg $397.80 and ROI 629.9, and 2050 avg $1,011.48 with ROI 1,755.9.
Overall, the forecast depicts a sustained bullish trend with significant potential upside by 2040 and beyond, while recognizing that these are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows the 2030 average price at $139.80 with a min of $109.01, a max of $190.99 and ROI of 156.5, with a bullish sentiment.
The forecast features a bullish sentiment from 2027 onward, with rising average prices and ROI: 2027 avg $71.44 (ROI 31.1%), 2028 avg $89.94 (ROI 65%), 2029 avg $115.43 (ROI 111.8%), culminating in 2030 avg $139.80 (ROI 156.5%) and 2050 avg $1,011.48 (ROI 1,755.9%). The data indicate upside, but these are estimates and not guarantees.
Yes. The 2029 average price is $115.43, which surpasses $100, with a min of $91.21 and a max of $154.96.
Current price is $54.50 and market cap is $31.38B.
The 30-day picture is bullish. RSI14 is 70, SMA50 is $49.13, SMA200 is $41.70, support is $48.43, resistance is $54.50, and the 30-day range is from $50.90 to $58.36.
Royalty Pharma plc Community Discussion
0Share your Royalty Pharma plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.